Literature DB >> 3182149

Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses.

A J Pinto1, P S Morahan, M A Brinton.   

Abstract

Several immunomodulators were compared for immunomodulatory and antiviral activity in B6C3F1 female mice. Our results demonstrate that murine recombinant gamma interferon (rIFN-G), human recombinant alpha A/D interferon (rIFN-A), ampligen (a polyribonucleotide) and CL246,738 modulate nonspecific immunity and are effective antiviral agents in vivo. Administration of each of these agents 1 day before cell harvest induced high levels of splenic natural killer (NK) cell activity against YAC-1 target cells. rIFN-G was also a potent activator of peritoneal macrophages (M phi), as evidenced by high levels of antitumor activity and changes in ectoenzyme phenotype that is characteristic of tumoricidal M phi. rIFN-A, ampligen and CL246,738 induced moderate to low levels of M phi activation by these criteria. In vivo protection experiments showed that repeated therapeutic treatment with rIFN-A protected mice against i.p. infection with Venezuelan equine encephalitis (an alpha togavirus, VEE), Banzi (a flavivirus) and herpes simplex virus type 2 (HSV-2). Similar treatment with rIFN-G was effective against VEE and HSV-2, but ineffective against Banzi virus. A single prophylactic i.p. dose of ampligen 1 day before virus challenge was very effective against Banzi virus, moderately effective against HSV-2, and ineffective against VEE and Caraparu (a bunyavirus) infection. A single prophylactic oral dose of CL246,738 provided almost complete protection of mice against VEE, Banzi, and HSV-2, and also increased the mean survival time for Caraparu infected mice. Collectively, these results indicate that rIFN-A, r-IFN-G, ampligen and CL246,738 may be useful in prophylactic or early therapeutic treatment of several serious virus infections. Since these agents stimulate NK cells and M phi, their antiviral activity may result, in part, from the alterations they induce in the natural immune system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182149     DOI: 10.1016/0192-0561(88)90050-1

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  10 in total

1.  Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice.

Authors:  Aaron L Olsen; John D Morrey; Donald F Smee; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-20       Impact factor: 5.970

2.  Prophylactic treatment with recombinant Eimeria protein, alone or in combination with an agonist cocktail, protects mice from Banzi virus infection.

Authors:  Justin G Julander; John W Judge; Aaron L Olsen; Barnett Rosenberg; Kristiina Schafer; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-04       Impact factor: 5.970

3.  Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft.

Authors:  H R Hubbell; H E Vargas; K L Tsujimoto; G D Gibson; E C Pequignot; R D Bigler; W A Carter; D R Strayer
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Role of macrophages in the host response to Lewis lung peritoneal carcinomatosis.

Authors:  M W Barth; P S Morahan
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

5.  C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection.

Authors:  Justin G Julander; Ramona Skirpstunas; Venkatraman Siddharthan; Kristiina Shafer; Justin D Hoopes; Donald F Smee; John D Morrey
Journal:  Antiviral Res       Date:  2008-02-13       Impact factor: 5.970

6.  Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge.

Authors:  Jennifer L Konopka; Joseph M Thompson; Alan C Whitmore; Drue L Webb; Robert E Johnston
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

Review 7.  Medicinal Plants and Isolated Molecules Demonstrating Immunomodulation Activity as Potential Alternative Therapies for Viral Diseases Including COVID-19.

Authors:  Hassan A Alhazmi; Asim Najmi; Sadique A Javed; Shahnaz Sultana; Mohammed Al Bratty; Hafiz A Makeen; Abdulkarim M Meraya; Waquar Ahsan; Syam Mohan; Manal M E Taha; Asaad Khalid
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 8.  Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development.

Authors:  Anuj Sharma; Barbara Knollmann-Ritschel
Journal:  Viruses       Date:  2019-02-18       Impact factor: 5.048

9.  A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

Authors:  Craig W Day; Ralph Baric; Sui Xiong Cai; Matt Frieman; Yohichi Kumaki; John D Morrey; Donald F Smee; Dale L Barnard
Journal:  Virology       Date:  2009-10-22       Impact factor: 3.616

Review 10.  Cytokine determinants of viral tropism.

Authors:  Grant McFadden; Mohamed R Mohamed; Masmudur M Rahman; Eric Bartee
Journal:  Nat Rev Immunol       Date:  2009-08-21       Impact factor: 53.106

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.